Figure 5
Figure 5. HDACIs reduce the levels of Rho-GTPase family members in murine fetal liver–derived megakaryocytes and the human megakaryoblastic cell line Meg-01. (A) Western blot performed on fetal liver cell–derived megakaryocytes treated for 48 hours with 10 nM panobinostat (Pan) and 1 nM romidepsin (Romi) showing a reduction in CDC42, Rac1, and RhoA, but no change in PAK1 or ROCK1 levels. (B) Western blot performed on Meg-01 cells treated for 24 hours with 20 nM panobinostat and 20 nM romidepsin showing a reduction in CDC42, Rac1, and RhoA, but no change in PAK1 or ROCK1 levels. The arrow indicates the corrected loading control.

HDACIs reduce the levels of Rho-GTPase family members in murine fetal liver–derived megakaryocytes and the human megakaryoblastic cell line Meg-01. (A) Western blot performed on fetal liver cell–derived megakaryocytes treated for 48 hours with 10 nM panobinostat (Pan) and 1 nM romidepsin (Romi) showing a reduction in CDC42, Rac1, and RhoA, but no change in PAK1 or ROCK1 levels. (B) Western blot performed on Meg-01 cells treated for 24 hours with 20 nM panobinostat and 20 nM romidepsin showing a reduction in CDC42, Rac1, and RhoA, but no change in PAK1 or ROCK1 levels. The arrow indicates the corrected loading control.

Close Modal

or Create an Account

Close Modal
Close Modal